- Home
- MYO vs OBIO Comparison
MYO vs OBIO Comparison
Compare MYO & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYO
- OBIO
- Stock Information
- Founded
- MYO 2004
- OBIO 2017
- Country
- MYO United States
- OBIO United States
- Employees
- MYO N/A
- OBIO N/A
- Industry
- MYO Industrial Specialties
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- MYO Health Care
- OBIO Health Care
- Exchange
- MYO Nasdaq
- OBIO Nasdaq
- Market Cap
- MYO 178.4M
- OBIO 151.3M
- IPO Year
- MYO 2017
- OBIO N/A
- Fundamental
- Price
- MYO $4.87
- OBIO $4.40
- Analyst Decision
- MYO Strong Buy
- OBIO Strong Buy
- Analyst Count
- MYO 4
- OBIO 5
- Target Price
- MYO $9.75
- OBIO $15.40
- AVG Volume (30 Days)
- MYO 637.2K
- OBIO 54.3K
- Earning Date
- MYO 03-10-2025
- OBIO 05-12-2025
- Dividend Yield
- MYO N/A
- OBIO N/A
- EPS Growth
- MYO N/A
- OBIO N/A
- EPS
- MYO N/A
- OBIO N/A
- Revenue
- MYO $32,551,198.00
- OBIO $2,647,000.00
- Revenue This Year
- MYO $32.15
- OBIO $22.61
- Revenue Next Year
- MYO $17.59
- OBIO $16.64
- P/E Ratio
- MYO N/A
- OBIO N/A
- Revenue Growth
- MYO 69.17
- OBIO N/A
- 52 Week Low
- MYO $2.51
- OBIO $3.75
- 52 Week High
- MYO $7.17
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- MYO 42.42
- OBIO 47.67
- Support Level
- MYO $5.28
- OBIO $4.14
- Resistance Level
- MYO $5.62
- OBIO $4.64
- Average True Range (ATR)
- MYO 0.33
- OBIO 0.32
- MACD
- MYO 0.00
- OBIO 0.08
- Stochastic Oscillator
- MYO 2.72
- OBIO 63.39
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.